IL278207A - Use of neutrophil elastase inhibitors in liver disease - Google Patents
Use of neutrophil elastase inhibitors in liver diseaseInfo
- Publication number
- IL278207A IL278207A IL278207A IL27820720A IL278207A IL 278207 A IL278207 A IL 278207A IL 278207 A IL278207 A IL 278207A IL 27820720 A IL27820720 A IL 27820720A IL 278207 A IL278207 A IL 278207A
- Authority
- IL
- Israel
- Prior art keywords
- liver disease
- neutrophil elastase
- elastase inhibitors
- inhibitors
- neutrophil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662074P | 2018-04-24 | 2018-04-24 | |
| PCT/US2019/028551 WO2019209738A1 (en) | 2018-04-24 | 2019-04-22 | Use of neutrophil elastase inhibitors in liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL278207A true IL278207A (en) | 2020-11-30 |
Family
ID=68236763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278207A IL278207A (en) | 2018-04-24 | 2020-10-21 | Use of neutrophil elastase inhibitors in liver disease |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10806735B2 (https=) |
| EP (1) | EP3784657A4 (https=) |
| JP (1) | JP2021522247A (https=) |
| KR (1) | KR20210002573A (https=) |
| CN (1) | CN113614070A (https=) |
| AU (2) | AU2019257632A1 (https=) |
| CA (1) | CA3101274A1 (https=) |
| IL (1) | IL278207A (https=) |
| SG (1) | SG11202010521VA (https=) |
| TW (1) | TW202011965A (https=) |
| WO (1) | WO2019209738A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN114375193B (zh) | 2019-09-12 | 2024-05-14 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| JP2023539639A (ja) | 2020-08-25 | 2023-09-15 | イーライ リリー アンド カンパニー | Ｓｓａｏ阻害剤の多形 |
| US20220098184A1 (en) * | 2020-09-11 | 2022-03-31 | Terms Pharmaceuticals, Inc. | Solid dispersion formulations of an fxr agonist |
| CN114085173B (zh) * | 2021-10-18 | 2024-04-16 | 嘉兴学院 | 一种2-硝基-4-甲砜基苯甲醛的制备方法 |
| CN115976192A (zh) * | 2022-12-02 | 2023-04-18 | 西安华壹健康医学检验实验室有限公司 | 一种用ne基因表达量检测评估脂肪肝的方法 |
| CN117357508B (zh) * | 2023-11-03 | 2024-05-17 | 中山大学孙逸仙纪念医院 | 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用 |
| CN119499379B (zh) * | 2024-09-23 | 2025-09-05 | 广东医科大学 | Elane基因作为心力衰竭靶点的制药用途和西维来司他的新用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8288402B2 (en) * | 2007-12-20 | 2012-10-16 | Bayer Intellectual Property Gmbh | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use |
| US9475779B2 (en) * | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| BR112017004708A2 (pt) * | 2014-09-12 | 2017-12-05 | Tobira Therapeutics Inc | terapia de combinação de cenicriviroc para o tratamento de fibrose |
| WO2016050835A2 (en) | 2014-10-02 | 2016-04-07 | Ruprecht-Karls-Universität Heidelberg | Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component |
| JP2018501276A (ja) * | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| CN110981815A (zh) * | 2015-03-18 | 2020-04-10 | Ph制药有限公司 | 用于生产化合物的方法 |
| US10894054B2 (en) * | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
| WO2017081044A1 (en) | 2015-11-13 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
| GB201608453D0 (en) | 2016-05-13 | 2016-06-29 | Univ Liverpool | Muscle regeneration |
| EP3518918A4 (en) * | 2016-09-28 | 2020-04-22 | Eiger Biopharmaceuticals, Inc. | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS |
-
2019
- 2019-04-22 CA CA3101274A patent/CA3101274A1/en active Pending
- 2019-04-22 AU AU2019257632A patent/AU2019257632A1/en not_active Abandoned
- 2019-04-22 WO PCT/US2019/028551 patent/WO2019209738A1/en not_active Ceased
- 2019-04-22 US US16/390,970 patent/US10806735B2/en active Active
- 2019-04-22 EP EP19793755.0A patent/EP3784657A4/en not_active Withdrawn
- 2019-04-22 KR KR1020207033317A patent/KR20210002573A/ko not_active Ceased
- 2019-04-22 JP JP2020559442A patent/JP2021522247A/ja active Pending
- 2019-04-22 SG SG11202010521VA patent/SG11202010521VA/en unknown
- 2019-04-22 CN CN201980040583.1A patent/CN113614070A/zh active Pending
- 2019-04-24 TW TW108114343A patent/TW202011965A/zh unknown
-
2020
- 2020-09-21 US US17/027,617 patent/US20210069192A1/en not_active Abandoned
- 2020-10-21 IL IL278207A patent/IL278207A/en unknown
-
2024
- 2024-10-28 AU AU2024227697A patent/AU2024227697A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021522247A (ja) | 2021-08-30 |
| SG11202010521VA (en) | 2020-11-27 |
| AU2024227697A1 (en) | 2024-11-21 |
| AU2019257632A1 (en) | 2020-11-26 |
| CA3101274A1 (en) | 2019-10-31 |
| EP3784657A4 (en) | 2022-02-09 |
| CN113614070A (zh) | 2021-11-05 |
| EP3784657A1 (en) | 2021-03-03 |
| US20190321364A1 (en) | 2019-10-24 |
| US10806735B2 (en) | 2020-10-20 |
| KR20210002573A (ko) | 2021-01-08 |
| WO2019209738A1 (en) | 2019-10-31 |
| US20210069192A1 (en) | 2021-03-11 |
| TW202011965A (zh) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278207A (en) | Use of neutrophil elastase inhibitors in liver disease | |
| PL3999506T3 (pl) | Inhibitory parp1 | |
| EP3843714C0 (en) | CD73 INHIBITORS | |
| EP3497086A4 (en) | AMINOPYRIMIDINE SSAO INHIBITORS | |
| PL3429571T3 (pl) | Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych | |
| BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| SI3352584T1 (sl) | Sestavki in postopki za sintezo 5'-omejenih RNAjev | |
| PL3303654T3 (pl) | Podstawione w pozycji 2 benzimidazolowe inhibitory korozji | |
| PL4051688T3 (pl) | Inhibitory cd73 | |
| DK3806898T3 (da) | Gremlin-1-antagonist til anvendelse i behandling af cancer | |
| HRP20251694T1 (hr) | Optimizirano doziranje diaminofenotiazina u populacijama | |
| KR102068915B9 (ko) | 조직 인자 경로 억제제 항체 및 그의 용도 | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| PL3381451T3 (pl) | Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| PL3768284T3 (pl) | Kompozycje z fageliny entrecoccus do zastosowania w terapii | |
| IL263089A (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
| EP3615937A4 (en) | METHOD OF QUANTIFYING INTER-ALPHA INHIBITOR PROTEINS | |
| IL281357B (en) | cd73 inhibitors and their pharmaceutical uses | |
| EP3294338A4 (en) | MACROPINOCYTOSIS IN CANCER | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL258340A (en) | Quantifying met protein for cancer treatment | |
| EP3349731A4 (en) | COMBINATION OF TOPOISOMERASE I INHIBITORS WITH IMMUNOTHERAPY IN THE TREATMENT OF CANCER | |
| EP3958852A4 (en) | MINI SOFT GEL NAPROXEN COMPOSITION |